



## *Salmonella* isolates from urine cultures: serotypes and antimicrobial resistance in hospital settings

Rafael Oliveira dos Reis<sup>1,2</sup> · Maria Cristina Cecconi<sup>3</sup> · Loeci Timm<sup>3</sup> · Margarida Neves Souza<sup>4,2</sup> · Nilo Ikuta<sup>4,2</sup> · Jonas Michel Wolf<sup>4,2</sup> · Vagner Ricardo Lunge<sup>4,2</sup>

Received: 25 April 2018 / Accepted: 17 December 2018 / Published online: 22 February 2019  
© Sociedade Brasileira de Microbiologia 2019

### Abstract

This study investigated the serotypes and antimicrobial resistance of *Salmonella* isolates in urine cultures from 38 hospitalized patients. Nine serotypes were detected, and a large proportion was Typhimurium and Enteritidis. The strains presented resistance to 11 different antibiotics. Thirteen isolates (11 from serotype Typhimurium) exhibited multidrug resistance.

**Keywords** Nontyphoid *Salmonella* · Urinary tract infections · Multidrug resistance

*Salmonella* is an important pathogen causing approximately 550 million infections in the world per year [1]. Typhoid *Salmonella* (TS) serotypes (Typhi, Paratyphi A and B) are adapted to humans and cause typhoid fever, while nontyphoid *Salmonella* (NTS) serotypes infect a wide range of hosts, causing symptoms ranging from mild gastroenteritis to severe systemic infection. NTS has increasingly impacted human health, and it is responsible for approximately 93.8 million infections with 155,000 deaths per year [1, 2]. The clinical symptoms include diarrhea, fever, headache, and abdominal pain [3]. Infections by invasive NTS (iNTS) strains can also progress to severe life-threatening sepsis, a common cause of

bacteremia in children and adults. The diversity in the clinical manifestations is explained by several factors, highlighting the occurrence of a large range of virulence factors in the bacterial strains [3, 4]. Urinary tract infections (UTIs) by *Salmonella* are infrequent in routine hospital practice and rarely reported in the scientific literature, although they may cause serious morbidity in immunocompromised and even in immunocompetent patients [5–8]. The present study describes the serotype identification and antimicrobial resistance of *Salmonella* isolates from urine cultures of hospitalized patients.

A total of 38 *Salmonella* isolates were obtained from urine cultures in different hospitalized patients in Rio Grande do Sul state and sent to a public health laboratory (Laboratório Central do Rio Grande do Sul, LACEN-RS) from 2010 to 2015. Demographic data (such as hospital, city, and date of isolation; age and sex of the patients) were obtained in the clinical forms. The isolates were plated on *Salmonella/Shigella* solid media, and presumptive *Salmonella* colonies were cultured in Triple Sugar Iron (TSI), Urea, Citrate, and Lysine Iron Agar (LIA) slants (Probac, São Paulo, Brazil). The isolates were submitted to aerobic incubation at 37 °C for 24 h. Suspected *Salmonella* colonies were partially tested by agglutination with the main polyvalent O and H antisera (Probac, São Paulo, Brazil). Complete antigenic characterization was carried out for serotype identification in the National Reference Laboratory for Cholera and Enteric Diseases in the Institute Oswaldo Cruz (FIOCRUZ, Rio de Janeiro, RJ, Brazil) by the Kauffmann-White-Le Minor scheme [9].

All isolates were also submitted to DNA extraction and real-time polymerase chain reaction (PCR) targeting the *invA*

Associate editor: Jorge Sampaio

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s42770-019-00052-y>) contains supplementary material, which is available to authorized users.

✉ Rafael Oliveira dos Reis  
rafaelurcamp@gmail.com

- <sup>1</sup> Universidade da Região da Campanha (URCAMP), Bagé, Rio Grande do Sul, Brazil
- <sup>2</sup> Programa de Pós-Graduação em Biologia Celular e Molecular Aplicada à Saúde, Universidade Luterana do Brasil (ULBRA), Canoas, Rio Grande do Sul, Brazil
- <sup>3</sup> Laboratório Central do Estado do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
- <sup>4</sup> Laboratório de Diagnóstico Molecular, Universidade Luterana do Brasil (ULBRA), Canoas, Rio Grande do Sul, Brazil

gene as previously described [10]. Molecular detection of the two main serotypes (Enteritidis and Typhimurium) was further carried out by testing isolates with a duplex real-time PCR targeted to *safA* and *fliA-IS200* genes, respectively [11]. Resistance to twelve antibiotics (ampicillin, AMP; ciprofloxacin, CIP; nalidixic acid, NAL; nitrofurantoin, NIT; sulfamethoxazole + trimethoprim, SUT; cefoxitin, CFO; chloramphenicol, CLO; streptomycin, STR; gentamicin, GEN; tetracycline, TET; ceftazidime, CAZ; imipenem, IMP) was evaluated for all samples according to the Clinical and Laboratory Standards Institute document M100-S24 (CLSI 2014) [12, 13]. *Escherichia coli* ATCC 25922 was used as a standard control. Isolates with resistance to three or more categories of antibiotics were considered to be multidrug-resistant (MDR) [12, 13]. Data were analyzed using the Statistical Package for Social Sciences (SPSS, version 18.0, Chicago, IL). Pearson's chi-square and/or Fisher's exact tests were used to verify significant differences between qualitative variables, including serotypes and antimicrobial resistance profiles. All statistical tests in this study were two-sided, and *p* values < 0.05 were considered to be statistically significant.

The sociodemographic data demonstrated that *Salmonella* was more commonly isolated from women (23, 60.5%) and adults older than 45 years (21, 55.3%). All 38 isolates

presented positive results for anti-*Salmonella* polyvalent O/H antiserum and for the generic *Salmonella* PCR targeting the *invA* gene. Complete serotyping and real-time PCR analysis showed that all isolates were NTS, and a large proportion were serotypes Typhimurium (21, 55.3%) and Enteritidis (6, 15.8%). Another eight NTS serotypes were also identified: Newport, Infantis, Dublin, Give, Ndolo, Ohio, Saintpaul, and Panama (Table 1).

An antimicrobial susceptibility test was performed for 32 (84.2%) of the NTS isolates. Five (15.6%) isolates were sensitive to all antibiotics, while the other 27 (84.4%) exhibited resistance to the following antibiotics: NAL (17, 53.1%), TET (14, 43.8%), STR (12, 37.5%), AMP (10, 31.3%), NIT (10, 31.3%), GEN (7, 21.9%), CLO (3, 9.4%), SUT (3, 9.4%), CIP (1, 3.1%), CFO (1, 3.1%), and CAZ (1, 3.1%). Twenty (62.5%) of these isolates were from the most frequent serotype (Typhimurium) and exhibited resistance to NAL (13, 65%), TET (13, 65%), STR (10, 50%), AMP (9, 45%), NIT (5, 25%), GEN (5, 25%), CLO (3, 15%), SUT (3, 15%), CIP (1, 5%), CFO (1, 5%), and CAZ (1, 5%) (Supplementary Material).

In addition, 14 (43.7%) isolates were resistant to three or more antibiotic classes and were classified as MDR. These isolates were predominantly from the serotype Typhimurium

**Table 1** Sociodemographic variables of patients, serotypes, and MDR frequency in NTS isolated from urine cultures between 2010 and 2015 in southern Brazil

Variables	NTS isolates <i>n</i> (%)	Multidrug resistance (MDR)			<i>p</i> value**
		No MDR <i>n</i> (%)	MDR <i>n</i> (%)	Missing* <i>n</i>	
Sex					
Male	15 (39.5)	7 (53.8)	6 (46.2)	2	0.836
Female	23 (60.5)	11 (57.9)	8 (42.1)	4	
Age range					
0–5	2 (5.3)	0 (0)	0 (0)	2	0.173
6–18	3 (7.9)	1 (50)	1 (50)	1	
19–45	12 (31.6)	9 (81.8)	2 (18.2)	1	
> 45	21 (55.3)	8 (42.1)	11 (57.9)	2	
Serotype					
Typhimurium	21 (55.3)	9 (45)	11 (55)	1	–
Enteritidis	6 (15.8)	2 (66.7)	1 (33.3)	3	
Newport	3 (7.9)	2 (100)	1 (50)	0	
Infantis	2 (5.3)	1 (100)	0 (0)	1	
Dublin	1 (2.6)	1 (100)	0 (0)	0	
Give	1 (2.6)	1 (100)	0 (0)	0	
Ohio	1 (2.6)	1 (100)	0 (0)	0	
Panama	1 (2.6)	1 (100)	0 (0)	0	
Ndolo	1 (2.6)	0 (0)	1 (100)	0	
Saintpaul	1 (2.6)	0 (0)	0 (0)	1	
Total	38	18	14	6	

\*Number of isolates not evaluated for MDR

\*\*Chi-square calculation (No MDR vs MDR)

(11, 37.9%), but there was also one (3.1%) Enteritidis isolate, one (3.1%) Newport isolate, and one (3.1%) Ndolo isolate. There was no significant difference between the frequencies of MDR and the variables sex and age ( $p$  values  $>0.05$ ) (Table 1).

*Salmonella* isolation in nonenteric samples is not as common in laboratory practice [6]. Two previous studies demonstrated low frequencies (1.4 to 2.8%) of *Salmonella* isolated from urine in comparison with other clinical samples (mainly enteric) in the São Paulo state, Brazil [14, 15]. Despite this low occurrence, both old and recent scientific studies have reported the association of *Salmonella* in urine cultures with UTIs, mainly in immunocompromised and elderly hospitalized patients [16–20]. In the present study, we described 38 *Salmonella* isolates (all of them NTS) obtained from urine cultures of patients from seven different hospitals, five from Porto Alegre (the capital city) and two from two other important and populous cities of the Rio Grande do Sul state (Novo Hamburgo and Santa Maria). NTS was isolated from both sexes and all age groups with predominance in adults over 45 years of age, as observed in other reports [16, 17, 19, 21].

In the serological analysis, most NTS isolates were from serotype Typhimurium (21, 55.3%). This same serotype has been the most frequent serotype isolated from urine in previous reports [5, 17, 20]. Typhimurium has a complete arsenal of virulence genes to remain in certain environments, such as hospital settings. The invasiveness characteristics of this serotype also facilitate bacteremia and the occurrence of UTIs [3, 4]. Other studies have also shown that this serotype is etiologically associated with UTIs in South America [21, 22].

Bacterial resistance was observed to several antibiotics, such as AMP, CIP, NAL, NIT, SUT, CFO, CLO, STR, GEN, TET, and CAZ. In the clinical routine, AMP has been the most commonly employed to treat UTIs, but 31.3% of the *Salmonella* isolates demonstrated resistance to this antibiotic, as previously described [17]. In addition, MDR was observed in several strains, primarily those from serotype Typhimurium. In Brazil, a previous study demonstrated that 59.3% of Typhimurium isolates from human clinical cases exhibited MDR [23]. It was also observed that Typhimurium presented a higher level of resistance than all of the other serotypes. A major concern is the spread of some clones, such as the sequence type 313 (ST313), which has high mortality rates (approximately 25%) and is frequently associated with HIV and/or malaria infection and malnutrition in Sub-Saharan African [4]. This NTS group (ST313) has even already been reported in Brazil [24].

In conclusion, we determined that the Typhimurium serotype was present at a high frequency in urine samples from patients with urinary tract infection in a hospital setting. We also determined that this serotype was the most frequently associated with MDR. Special attention should be given to the prevention and hospital control of

urinary tract infections caused by the Typhimurium serotype.

**Acknowledgments** The authors wish to thank the members of the Bacteriology Department of the LACEN-RS and the Molecular Diagnostics Laboratory (ULBRA) for the assistance and technical support in the development of this study. We also thank the microbiology laboratories that sent the *Salmonella* cultures to LACEN-RS.

**Financial support** This research project was funded by Universidade Luterana do Brasil (ULBRA) and SIMBIOS Biotecnologia. Ikuta and Lunge were also financially supported by the National Council for Scientific and Technological Development from Brazil (CNPq – Conselho Nacional de Desenvolvimento Científico e Tecnológico; process numbers 313564/2014-0; 313304/2014-9). This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001. Reis, Souza and Wolf were further supported by the Coordination for the Improvement of Higher Education Personnel from Brazil (CAPES – Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; process number 181 – 18/12/2012).

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflicts of interest.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## References

1. WHO (2016) *Salmonella* (non-typhoidal) fact sheet n°167, December 2016. Available at: <http://www.who.int/mediacentre/factsheets/fs139/en/>. Accessed 05 March 2017
2. Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O'Brien SJ, Jones TF, Fazil A, Hoekstra RM, International Collaboration on Enteric Disease 'Burden of Illness' Studies (2010) The global burden of nontyphoidal *Salmonella* gastroenteritis. *Clin Infect Dis* 50: 882–889
3. Hensel M (2004) Evolution of pathogenicity islands of *Salmonella* enterica. *Int J Med Microbiol* 294:95–102
4. Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA (2012) Invasive non-typhoidal *Salmonella* disease: an emerging and neglected tropical disease in Africa. *Lancet* 379:2489–2499
5. Abbott SL, Portoni BA, Janda JM (1999) Urinary tract infections associated with nontyphoidal *Salmonella* serogroups. *J Clin Microbiol* 37:4177–4178
6. Mellon G, Delanoe C, Roux AL, Heym B, Dubourg O, Hardy P, Chevallier B, Perronne C, Rouveix E, Salomon J (2017) Non-typhi *Salmonella* enterica urinary tract infections. *Med Mal Infect*
7. Gorelik Y, Paul M, Geffen Y, Khamaisi M (2017) Urinary tract infections due to non typhoidal *Salmonella*. *Am J Med Sci* 353: 529–532
8. Jehangir A, Poudel D, Fareedy SB, Salman A, Qureshi A, Jehangir Q, Alweis R (2015) Group d salmonella urinary tract infection in an immunocompetent male. *Case Rep Infect Dis* 2015(608632)
9. Grimont PAD, Weill FX (2007). *Antigenic formulae of the Salmonella* serovars, seventh ed. Institut Pasteur, Paris. Available at: [https://www.pasteur.fr/sites/default/files/veng\\_0.pdf](https://www.pasteur.fr/sites/default/files/veng_0.pdf). Accessed 05 March 2017

10. Hoorfar J, Ahrens P, Rådström P (2000) Automated 5' nuclease PCR assay for identification of *Salmonella enterica*. *J Clin Microbiol* 38:3429–3435
11. Maurischat S, Baumann B, Martin A, Malorny B (2015) Rapid detection and specific differentiation of *Salmonella enterica* subsp. *enterica* Enteritidis, Typhimurium and its monophasic variant 4,[5], 12i:- by real-time multiplex PCR. *Int J Food Microbiol* 193:8–14
12. Crump JA, Medalla FM, Joyce KW, Krueger AL, Hoekstra RM, Whichard JM, Barzilay EJ, Emerging Infections Program NARMS Working Group (2011) Emerging infections program NARMS working group antimicrobial resistance among invasive nontyphoidal *Salmonella enterica* isolates in the United States: National Antimicrobial Resistance Monitoring System, 1996 to 2007. *Antimicrob Agents Chemother* 55:1148–1154
13. CLSI (2014) Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-four Informational Supplement; M100-S24. Wayne, PA, eleventh ed. New York
14. Fernandes SA, Tavechio AT, Ghilardi AC, Dias AM, Almeida IA, Melo LC (2006) *Salmonella* serovars isolated from humans in São Paulo state, Brazil, 1996–2003. *Rev Inst Med Trop Sao Paulo* 48: 179–184
15. de Castro FA Jr, dos Santos VR, Martins CH, Fernandes SA, Zaia JE, Martinez R (2002) Prevalence and antimicrobial susceptibility of *Salmonella* serotypes in patients from Ribeirão Preto, São Paulo, Brazil, between 1985 and 1999. *Braz J Infect Dis* 6:244–251
16. Tena D, González-Praetorius A, Bisquert J (2007) Urinary tract infection due to non-typhoidal *Salmonella*: report of 19 cases. *J Inf Secur* 54:245–249
17. Allerberger FJ, Dierich MP, Ebner A, Keating MR, Steckelberg JM, Yu PK, Anhalt JP (1992) Urinary tract infection caused by nontyphoidal *Salmonella*: report of 30 cases. *Urol Int* 48:395–400
18. Klosterman SA (2014) *Salmonella*-related urinary tract infection in an elderly patient. *BMJ Case Rep*. <https://doi.org/10.1136/bcr-2014-204552>
19. Seligmann E, Saphra I, Wassermann M (1946) *Salmonella* infections in the U.S.A.; a second series of 2,000 human infections recorded by the N.Y. *Salmonella* Center. *J Immunol* 54:69–87
20. Sivapalasingam S, Hoekstra RM, McQuiston JR, Fields PI, Tauxe RV (2004) *Salmonella* bacteriuria: an increasing entity in elderly women in the United States. *Epidemiol Infect* 132:897–902
21. Rodríguez EC, Díaz-Guevara P, Moreno J, Bautista A, Montaña L, Realpe ME, Della Gaspera A, Wiesner M (2017) Laboratory surveillance of *Salmonella enterica* from human clinical cases in Colombia 2005–2011. *Enferm Infecc Microbiol Clin* 35:417–425
22. EFSA, European food safety authority (2010) Scientific opinion on monitoring and assessment of the public health risk of “*Salmonella* Typhimurium-like” strains. *EFSA J* 8:1826. <https://doi.org/10.2903/j.efsa.2010.1826/epdf>
23. Reis ROD, Souza MN, Cecconi MCP, Timm L, Ikuta N, Simon D, Wolf JM, Lunge VR (2018) Increasing prevalence and dissemination of invasive nontyphoidal *Salmonella* serotype Typhimurium with multidrug resistance in hospitalized patients from southern Brazil. *Braz J Infect Dis* 18
24. Almeida F, Seribelli AA, da Silva P, Medeiros MIC, Dos Prazeres Rodrigues D, Moreira CG, Allard MW, Falcão JP (2017) Multilocus sequence typing of *Salmonella* Typhimurium reveals the presence of the highly invasive ST313 in Brazil. *Infect Genet Evol* 51:41–44